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Original articleAngptl4 serves as an endogenous inhibitor
of intestinal lipid digestionFrits Mattijssen 1, Sheril Alex 1, Hans J. Swarts 2, Albert K. Groen 3, Evert M. van Schothorst 2, Sander Kersten 1,*ABSTRACTDietary triglycerides are hydrolyzed in the small intestine principally by pancreatic lipase. Following uptake by enterocytes and secretion as
chylomicrons, dietary lipids are cleared from the bloodstream via lipoprotein lipase. Whereas lipoprotein lipase is inhibited by several proteins
including Angiopoietin-like 4 (Angptl4), no endogenous regulator of pancreatic lipase has yet been identiﬁed. Here we present evidence that Angptl4
is an endogenous inhibitor of dietary lipid digestion. Angptl4 / mice were heavier compared to their wild-type counterparts without any
difference in food intake, energy expenditure or locomotor activity. However, Angptl4 / mice showed decreased lipid content in the stools and
increased accumulation of dietary triglycerides in the small intestine, which coincided with elevated luminal lipase activity in Angptl4 / mice.
Furthermore, recombinant Angptl4 reduced the activity of pancreatic lipase as well as the lipase activity in human ileostomy output. In conclusion,
our data suggest that Angptl4 is an endogenous inhibitor of intestinal lipase activity.
& 2013 The Authors. Published by Elsevier GmbH.
Keywords Angptl4; Pancreatic lipase; Intestine; Obesity
Open access under CC BY-NC-ND license.1. INTRODUCTION
Dietary triglycerides (TGs) contribute a major portion of our daily energy
requirement. TGs are digested in the gastrointestinal tract through the
action of several lipases including lingual lipase and gastric lipase [1,2].
However, the far majority of dietary TGs are digested in the small
intestine by pancreatic lipase (PL) assisted by pancreatic colipase,
pancreatic lipase-related protein 2, and carboxyl ester lipase [3,4]. To
increase the accessibility of PL to dietary TGs at the oil–water
interphase, dietary lipids are emulsiﬁed by the action of bile acids,
which are produced in the liver, stored in the gallbladder, and
subsequently released upon ingestion of a high-fat meal [2,5]. The
resulting mono-acylglycerol and free fatty acids are taken up by
enterocytes and resynthesized into TGs, followed by the lipidation of
apolipoproteins to yield chylomicrons that are subsequently secreted into
the lacteals [6–8]. After traveling through the splanchnic lymphatic
system and the thoracic duct, chylomicrons are released into the blood
stream and ultimately reach the heart, skeletal muscle and adipose
tissue as their primary target organs.
Clearance of circulating chylomicrons is mediated by lipoprotein lipase
(LPL), which is anchored to the capillary endothelium via the protein
GPIHBP1 [9–11]. LPL catalyzes the hydrolysis of TGs to free fatty acids,
which are taken up by the parenchymal cells to serve as energy source,
building blocks for membranes, or to be used for storage. LPL is thought
to function as an active homodimer and its activity in tissues is profoundlyhttp://dx.doi.org/10.1016/j.molmet.2013.11.004
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MOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Authors. Published by Elsevier GmbH.Opeinﬂuenced by various physiological stimuli, including nutritional status,
exercise and cold [9]. In the last decade it has become evident that the
activity of LPL is carefully controlled by three proteins belonging to the
Angiopoietin-like protein family: Angptl3, Angptl4, and Angptl8 [12,13]. All
three proteins have been shown to inhibit LPL activity in vitro and in vivo
and accordingly raise circulating TG levels [12,14,15]. Angptl3 is produced
primarily by the liver and its expression is regulated by the Liver X
Receptor [16,17]. Angptl8, a paralog of Angptl3, was recently identiﬁed as
the latest member of the Angptl family [13]. Deletion of Angptl8 results in
decreased plasma TG levels due to decreased hepatic VLDL production
and elevated LPL activity [14]. Angptl4 has previously been shown to
potently inhibit LPL in several tissues and cells under a variety of
circumstances. Indeed, we and others have identiﬁed Angptl4 as an
important regulator of LPL in adipose tissue, heart, and macrophages
[18–22]. Angptl4 forms higher order oligomers and is subject to
proteolytic cleavage to yield C- as well as N-terminal Angptl4. The
precise mechanism by which Angpl4 inhibits LPL as well as the
localization of the inhibitory effect are not fully understood. It was
reported that Angptl4 inhibits LPL by promoting the irreversible conversion
of active homodimeric units into inactive monomers [23], whereas recent
data suggest that Angptl4 functions as a reversible noncompetitive
inhibitor of LPL [24]. The expression of Angptl4 is governed by a
multitude of dietary and hormonal cues including fatty acids and
glucocorticoids via peroxisome proliferator-activated receptors (PPARs)
and glucocorticoid receptor (GR), respectively [25–27].eg 2, 6703 HD Wageningen, The Netherlands 2Human and Animal Physiology, Department of Animal
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Original articleLPL is a part of the same family of extracellular lipases as PL, which
also include endothelial lipase and hepatic lipase [28]. However, little is
known about regulation of the activity of PL. Here we report that Angptl4
reduces intestinal lipase activity by inhibition of PL. As a result,
Angptl4 / animals harvest more lipids from ingested food resulting
in increased fat mass and body weight.2. MATERIAL AND METHODS
2.1. Animal studies
Animals used for all experiments were pure-bred male wild-type and
Angptl4 / animals on a C57BL/6 background [29]. Body composition
was determined by DEXA (Lunar, PIXImus) on chow-fed 24 weeks
old wild-type and Angptl4 / mice. Food intake was recorded over a
2-week period. Animals were sacriﬁced by cervical dislocation after
being anesthetized using isoﬂurane and several organs were excised.
Eleven week old wild-type and Angptl4 / animals were given access
to HFD providing 45en% fat (D12451, Research Diets Services, Wijk bij
Duurstede, The Netherlands). Food intake and body weight were
recorded weekly for a period of 3 weeks.
Wild-type and Angptl4 / animals (28 weeks old) were analyzed in an
open-circuit LabMaster Metabolism Research Platform (TSE systems
GmbH, Bad Homburg, Germany) as described previously [30], with
minor adaptations. Animals were acclimatized for 24 h followed by 48 h
measurements. Eight of the 12 cages were also equipped for locomotor
activity measurements. Body composition analysis (Echo-MRI, Houston,
USA) was performed immediately before and after the indirect calori-
metric analyses, which showed similar lean mass between wild-type
and Angptl4 / mice. One week before the actual metabolic
phenotyping, the animals were switched to HFD. During the analysis,
mice were kept on the same HFD. Fecal fat was extracted from feces of
11-week old wild-type and Angptl4 / animals after a 3-week HFD
intervention using published methods [31]. Fatty acids were subse-
quently measured using an enzymatic assay (NEFA-HR(2), Wako
Chemicals, Neuss, Germany).
Intestinal lipid absorption tests were performed using 3H-labeled triolein
according to published methods [32]. For determination of intestinal TG
content, wild-type and Angptl4 / animals were fed a HFD for 24 h
after a 1 week run in with LFD. Mice were killed by cervical dislocation
and the small intestine was collected, washed with ice-cold PBS and
snap frozen. Samples were homogenized in sucrose buffer (10 mM Tris,
2 mM EDTA, 0.25 M sucrose, pH 7.5) with a Qiagen TissueLyser II
(Qiagen, Hilden, Germany) and subsequently analyzed for TGs using a
Triglycerides liquicolormono kit (HUMAN, Wiesbaden, Germany).
qPCR analysis of PPARα target genes was performed in proximal small
intestine of 10–15-week-old wild-type and Angptl4 / mice fed LFD
or a safﬂower oil-based HFD for 6 weeks. qPCR analysis of Pparα target
genes was also performed on small intestine of 4-month-old wild-type
and Angptl4 / animals fasted for 4 h and subsequently intragas-
trically gavaged with 400 μL carboxymethyl cellulose (CMC) or synthetic
trilinolenin. Proximal small intestines were excised, washed with ice-
cold PBS, and subsequently snap frozen in liquid nitrogen.
To assess intestinal transit time, wild-type and Angptl4 / mice
(16-week old) were fed AIN-93W low fat semi-puriﬁed diet (Research
Diets Services, Wijk bij Duurstede, Netherlands) for 3 days prior to the
experiment. Next, the mice were fasted for 16 h and subsequently given
access to AIN-93W diet which was colored with 60 mg/kg Fast Green
FCF (Sigma-Aldrich, Schnelldorf, Germany). The time until the ﬁrst green
dropping appeared was recorded. Feces from 12–15-week-old wild-136 MOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Autype and Angptl4 / mice on standard chow were collected and
analyzed for several bile acids as described previously [33].
Animal studies were performed according to protocols approved by the
local animal ethics committee of Wageningen University.2.2. Gene expression analysis
Proximal intestine samples from wild-type and Angplt4 / animals
after HFD or lipid gavage were homogenized in TRIzols (Life
Technologies Europe BV, Bleiswijk, The Netherlands) using a Qiagen
TissueLyser II (Qiagen, Hilden, Germany) for RNA isolation. cDNA was
synthesized with the First Strand cDNA synthesis kit (Thermo Scientiﬁc,
Landsmeer, The Netherlands). qPCR was performed using SensiMix
(Bioline, GC biotech, Alphen aan den Rijn, The Netherlands) and primers
from the Harvard PrimerBank on a CFX384 platform (BioRad, Veenen-
daal, The Netherlands). For normalization 36b4 was used as a
housekeeping gene. Affymetrix GeneChip analysis was performed on
10 longitudinal small intestine fragments collected along the total length
of the small intestine of C57BL/6 mice fed LFD or HFD for 2 weeks. RNA
was extracted as described above and subsequently puriﬁed using the
RNeasy Minikit (Qiagen, Venlo, The Netherlands). RNA quality was
assessed on RNA 6000 Nano chips with the Agilent 2100 Bioanalyzer
(Agilent Technologies, Amsterdam, the Netherlands). Labeled RNA was
hybridized to Affymetrix Mouse Gene 1.1 ST array plate on the
Affymetrix GeneTitan platform, and scans were processed using
Bioconductor followed by RMA normalization [34,35]. Probe sets were
generated based on published methods [36] using chip deﬁnition ﬁle
(CDF) version 15 derived from the Entrez gene database. Analysis of
Villin and Angptl mRNA levels along the crypt-villus axis was performed
according to published methods [37] using qPCR as described above.2.3. Mouse luminal lipase activity
Luminal content collected from the small intestine was mixed with 19
volumes ice-cold PBS, vortexed vigorously and centrifuged at 15,000g/
4 1C for 10 min. Supernatants were collected and diluted 1:100 in PBS
for subsequent analysis. Lipase activity was measured using the Roar
LPL activity assay kit (Roar Biomedical, Inc., New York, USA) according
to the manufacturer's protocol. The LPL activity kit employs a substrate
that becomes ﬂuorescent upon hydrolysis of an ester and can be used to
assess the activity of other lipases too. Lipase activity was calculated as
mmol/h using a pre-hydrolyzed substrate and subsequently normalized
for protein concentration of the fecal water as determined with BCA
protein assay (Thermo Fisher Scientiﬁc, Landsmeer, The Netherlands).2.4. Human luminal lipase activity
Three otherwise healthy volunteers with a distal ileostomy volunteered to
provide stoma output. Volunteers were aged 50–67 years and included
one male and two females. Collected material was transported on ice
and centrifuged at 5000g/4 1C for 10 min. Supernatants were collected
and stored at 80 1C until lipase activity assays. Samples were diluted
1:100 before determining lipase activity with the Roar LPL Activity Assay
Kit. Recombinant mouse Angptl4 (R&D Systems, Abingdon United
Kingdom) or Orlistat (Sigma-Aldrich, Schnelldorf, Germany) were allowed
to pre-incubate with stoma output at 37 1C for 45 min after which the
ﬂuorescent substrate was added. Fluorescence was measured after an
additional incubation period at 37 1C for 45 min. Fluorescent units were
converted to mmol of hydrolyzed substrate per hour using the pre-
hydrolyzed substrate, and normalized for protein content determined
with a BCA protein assay.thors. Published by Elsevier GmbH. www.molecularmetabolism.comOpen access under CC BY-NC-ND license.
Figure 1: Angptl4 / mice are heavier despite equal food intake. (A–D) Body weight (A), fat mass as determined with DEXA scan (B), average food intake per day over a 2-week period (C) of
wild-type and Angptl4 / mice on a standard chow diet (n¼10–11 per group). (D and E) Body weight development (D) and food intake (E) of wild-type and Angptl4 / mice after a switch
to HFD (n¼4–5 per group). Data are mean7SEM. Asterisks indicate significant differences according to Student’s t-test; * pr0.05, ** pr0.01.2.5. Pancreatic lipase activity
Recombinant PL (Sigma-Aldrich, Schnelldorf, Germany) at an amount of
250 units was added to the ﬂuorescent substrate of the Roar LPL Activity
Assay Kit. Recombinant mouse Angptl4 or Orlistat were included to address
the inhibitory capacity of these compounds on PL mediated hydrolysis.
Fluorescence was measured after incubation at 37 1C for 45 min.
2.6. Statistical analysis
Unpaired two-tailed Student's t-tests and analysis of variances with
corresponding post-hoc tests were performed using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA). The cutoff for signiﬁcance level
was set at pr0.05.3. RESULTS
3.1. Angptl4 deletion leads to increased bodyweight independent of
food intake, energy intake, or locomotor activity
We observed that chow-fed Angptl4 / mice have a signiﬁcantly higher
bodyweight than age-matched wild-type mice (Figure 1A). Body composi-
tion analysis by DEXA indicated that the difference in body weight can be
attributed to a higher amount of body fat (Figure 1B). In contrast, no
difference in lean mass was observed between the two sets of mice, which
was supported by the weight of major organs including liver, heart, and
various muscles (Figure S1A–F). Also, no differences in food intake could be
recorded (Figure 1C). Supporting a role of Angptl4 in dietary fat-induced
weight gain, Angptl4 / mice gained weight much faster compared to
wild-type mice when switched to a high fat diet (Figure 1D), which again
was independent of food intake (Figure 1E).
A difference in body weight can be explained by several mechanisms
including differences in locomotor activity and/or energy expenditure.MOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Authors. Published by Elsevier GmbH.OpeTo explore these options we determined the total energy balance of wild-
type and Angptl4 / mice using indirect calorimetry. For 1 week prior to
and during the measurements the mice were given access to HFD. The
metabolic phenotyping revealed no differences in food intake (Figure 2A and
B) and energy expenditure (Figure 2C and D), which was conﬁrmed with
ANCOVA analysis. Respiratory exchange ratios for wild-type and Angptl4 /
 animals were equal at 0.85, indicative of the combustion of a mixture of
fat and carbohydrates (Figure 2E). Moreover, locomotor activity did not differ
between wild-type and Angptl4 / animals (Figure 2F). These data
indicate that the enhanced fat mass in Angptl4 / mice is not due to
increased food intake or decreased energy expenditure.
To examine if lipid absorption is elevated in Angptl4 / mice, we
determined the amount of fat in the feces in mice fed low fat diet or high
fat diet. Strikingly, the amount of fat in the feces was signiﬁcantly lower
in Angptl4 / mice as compared to wild-type mice (Figure 2G),
indicating enhanced lipid absorption. Thus, the data suggest that
Angptl4 / mice harvest more lipids from the ingested food, pointing
to the intestine as a key site of Angptl4 action.
Although Angptl4 is known to be produced by a number of intestinal cell
lines [38,39], little is known about intestinal Angptl4 expression in vivo. In
mouse small intestine, Angptl4 mRNA levels were highest at the top of the
villi and lowest in the crypts (Figure 3A). Expression of Angptl4 did not vary
much along the longitudinal axis of the murine small intestine (Figure 3B).
Interestingly, except in the most proximal portion of the small intestine,
Angptl4 mRNA levels were 2–3 fold elevated by high fat feeding (Figure 3B).
To explore the possible cause for the increased harvesting of dietary fat
we carried out a lipid absorption test via oral dosing of 3H-triolein. No
difference was observed in the rate of appearance of 3H-tracer in the
circulation between wild-type and Angptl4 / mice (Figure 4A),
indicating that chylomicron synthesis and secretion, which are rate-
limiting for dietary TG entry into the blood, are not different between the137www.molecularmetabolism.comn access under CC BY-NC-ND license.
Figure 2: Metabolic phenotyping reveals no differences in energy expenditure, food intake or locomotor activity between wild-type and Angptl4 / mice. (A and B) Food intake per 2 h (A)
or accumulated over 2 days (B) of wild-type and Angptl4 / mice on a 45en% HFD diet (n¼11–12 per group). (C) Energy expenditure as determined every 13 min over the course of 2 days
(n¼11–12 per group). (D) Average energy expenditure over 2 days of wild-type and Angptl4 / animals (n¼11–12 per group). (E) RER of wild-type and Angptl4 / animals (n¼11–12
per group). (F) Locomotor activity of wild-type and Angptl4 / animals (n¼7–8 group). (G) Fecal fat content in wild-type and Angptl4 / mice after a 3-week HFD intervention (n¼4–5
group). Data are mean7SEM. Asterisk indicates significant differences according to two-way ANOVA with Bonferroni post-hoc test; * pr0.05.
Original articletwo sets of mice. However, a signiﬁcant increase in tracer abundance
was observed in small intestinal tissue of Angptl4 / mice
(Figure 4B), suggesting a higher rate of fatty acid uptake and possibly
digestion. This ﬁnding was conﬁrmed by higher TG levels in small
intestine of Angptl4 / mice after a 1-day HFD intervention
(Figure 4C). In accordance with activation of the lipid-sensitive
transcription factor PPARα by dietary fat, HFD or lipid gavage caused
marked induction of numerous PPARα target genes in the small
intestine. Consistent with enhanced lipid uptake in Angptl4 / mice,
induction of PPARα targets by HFD or lipid gavage was markedly
augmented in Angptl4 / mice in comparison with wild-type mice
(Figure 5A and B). These data suggest that Angptl4 regulates the
amount of luminal TG entering the enterocytes while having no effect on
the amount of TG released from the intestine into the circulation.138 MOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Au3.2. Increased lipid digestion in Angptl4 / mice is independent of
intestinal length, gastrointestinal transit time, and bile acid secretion or
composition
An increase in intestinal lipid uptake might be explained by several
factors, including a decrease in gastrointestinal (GI) transit time, allowing
more time for lipases to digest dietary TG and causing a higher overall
rate of lipid digestion. To explore this possibility we fed overnight fasted
mice a semi-synthetic diet colored with Fast Green FCF and recorded
the time until arrival of the ﬁrst dropping. No difference was observed in
GI transit time between wild-type and Angptl4 / mice (Figure 6A). In
addition, total length of the small intestine was unchanged between
wild-type and Angptl4 / mice (Figure 6B).
Bile acids play an important role in lipid digestion by emulsifying lipids and
thereby allowing for increased efﬁciency of lipid harvesting. Hence, athors. Published by Elsevier GmbH. www.molecularmetabolism.comOpen access under CC BY-NC-ND license.
Figure 3: Increased intestinal Angptl4 mRNA expression after a HFD intervention. (A) Villin and Angptl4 expression in isolated epithelial fractions enriched for villi (n¼2). (B) Angptl4 expression in
10 parts of the small intestine after 2 weeks HFD intervention, determined with Affymetrix Microarray (n¼3). Data are mean7SEM. Asterisks indicate significant differences according to Student’s
t-test; * pr0.05, ** pr0.01.
Figure 4: Angptl4 / mice accumulate fat in their intestine. (A and B) 3H-triolein appearance in plasma (A) and intestine (B) after gavage with 3H-triolein in fasted wild-type and Angptl4 /
mice (n¼8–10 per group). (C) Triglyceride content of wild-type and Angptl4 / intestine after one day HFD intervention (n¼6–7 per group). Data are mean7SEM. Asterisk indicates
significant differences according to Student’s t-test; * pr0.05.difference in the composition or in the total amount of bile acids may
contribute to increased lipid uptake. We found no difference in the fecal
amount of cholic- or deoxycholic acid (Figure 6C), nor in the amount of
primary-, secondary-, or total bile acids between wild-type and Angptl4 /
 mice (Figure 6D and E). Together, these observations indicate that
enhanced lipid uptake in intestine of Angptl4 / mice is unrelated to
changes in intestinal transit time, intestinal length or bile acid composition/
secretion.MOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Authors. Published by Elsevier GmbH.Op3.3. Angptl4 inhibits pancreatic lipase
Angptl4 serves as an endogenous inhibitor of LPL and there is evidence
that it inhibits hepatic lipase as well [40]. Since PL, which serves as the
principal intestinal lipase, belongs to the same family of extra-cellular
lipases, we asked whether increased lipid uptake in Angptl4 / mice
may be explained by enhanced lipid digestion due to a lack of Angptl4-
mediated inhibition of intestinal lipase activity. To test this hypothesis we
collected the luminal content from (refed) wild-type and Angptl4 /139www.molecularmetabolism.comen access under CC BY-NC-ND license.
Figure 5: Expression of Ppar target genes is increased in Angptl4 / mice intestine. (A and B) Expression of selected Ppar targets in the proximal part of the small intestine after a 6-week HFD
intervention (A, n¼6–7 per group) or oral gavage with 0.5% carboxymethyl cellulose (CMC) or C18:3 triglycerides (B, n¼5–6 per group) in wild-type and Angptl4 / mice. Data are
mean7SEM. Asterisks indicate significant differences according to two-way ANOVA with Bonferroni post-hoc test; * pr0.05, ** pr0.01.
Figure 6: Increased lipid uptake in Angptl4 / mice is independent of transit time or bile acid secretion. (A and B) GI transit time (A) and intestinal length (B) of wild-type and Angptl4 /
mice (n¼8–9 per group). (C–E) Fecal bile acids in wild-type and Angptl4 / mice expressed as CA vs. CDCA (C), primary vs. secondary (D), or total (E) bile acids (n¼8–9 per group). Data
are mean7SEM.
Original article
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Figure 7: Angptl4 inhibits pancreatic lipase. (A) Luminal lipase activity in fecal water derived from wild-type and Angptl4 / mice (n¼9 per group). (B) Recombinant PL activity in the presence
of increasing concentrations of Orlistat or recombinant Angptl4. (C) Lipase activity in stoma output of human volunteers (in the absence or presence of Orlistat 25 M) or recombinant human Angptl4
(10 g/ml) (n¼3). Data are mean7SEM. Asterisks indicate significant differences according to Student’s t-test (A) or one-way ANOVA with Tukey’s post-hoc test (C); * pr0.05, ** pr0.01.mice and assayed fecal water for lipase activity. Consistent with our
hypothesis, Angptl4 / mice had a signiﬁcantly higher luminal lipase
activity in comparison to wild-type mice (Figure 7A).
Inasmuch as PL is responsible for the major portion of intestinal lipase
activity, we determined the direct effect of Angptl4 on PL by assaying the
activity of recombinant PL in the presence of increasing amounts of
recombinant Angptl4. As shown in Figure 7B, Angptl4 inhibited PL activity in
a dose-dependent manner. To extend these ﬁndings we collected ileostomy
output from three otherwise healthy humans. Similar to mouse intestinal
content, human material contained high lipase activity, which was
repressed by the PL inhibitor Orlistat (Figure 7C). Importantly, adding
recombinant human Angptl4 signiﬁcantly decreased the luminal lipase
activity (Figure 7C). Together, these data indicate that Angptl4 inhibits
intestinal lipase activity.4. DISCUSSION
Our results indicate that Angptl4 serves as an endogenous inhibitor of
dietary lipid digestion via inhibition of PL, reducing the amount of energyMOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Authors. Published by Elsevier GmbH.Opethat is harvested from dietary fat. As a result, mice lacking Angptl4 have
less fat in their feces and gain more weight over time. Loss of Angptl4 does
not appear to have any effect on energy expenditure or food intake. A key
question elicited by our study is: what is the physiological relevance of an
endogenous intestinal lipase inhibitor, production of which is increased by
dietary fat? It is generally accepted that chylomicron secretion is rate
limiting for lipid absorption, as evidenced by the constant rate of TG entry
into the blood during an oral lipid loading test. Following consumption of a
copious fat-rich meal, absence of any regulation on TG digestion may be
expected to lead to excess fatty acid uptake into enterocytes, exceeding the
capacity for re-esteriﬁcation and chylomicron secretion and thus leading to
lipid overload. To avoid such a scenario, production of Angptl4 is quickly
stimulated upon entry of dietary fatty acids into enterocytes, putting a brake
on dietary TG digestion. We propose that Angptl4 is an essential component
of a feedback mechanism aimed at matching lipid uptake into enterocytes
to the capacity for TG secretion. Previously, a similar role for Angptl4 in
protection against lipid overload was demonstrated in cardiomyocytes and
macrophages [19,20].
The mechanism by which Angptl4 inhibits PL at the biochemical level
requires further investigation. While we present a compelling case for141www.molecularmetabolism.comn access under CC BY-NC-ND license.
Original articledirect inhibition of PL by Angptl4 as the underlying mechanism
accounting for enhanced fat uptake in Angptl4 / mice, we cannot
completely exclude a potential effect of Angptl4 deletion on total PL
secretion. Indeed, an increase in PL secretion in Angptl4 / mice
would lead to increased lipid uptake and decreased fat secretion in the
stools. However, recombinant Angptl4 was able to inhibit pancreatic
lipase, pointing to a direct effect on PL. Since PL does not function as a
homodimer, Angptl4 cannot inhibit PL by promoting the irreversible
dimer to monomer conversion, as has been proposed for LPL [23].
Interestingly, recent data suggest that Angptl4 may reversibly inhibit LPL
independent of dimer dissociation by forming an inhibitory complex with
LPL that regains lipase activity upon dissociation [24]. It can be
hypothesized that a similar mechanism may underlie inhibition of PL
by Angptl4. It should be noted that Angptl4 was able to inhibit PL in the
absence of colipase, and we therefore believe it is unlikely that the
inhibitory effect is attributable to interference of the interaction between
PL and colipase. Although the Angptl4 concentrations required for
in vitro PL inhibition were relatively high, in vitro inhibition of LPL by
Angptl4 under similar conditions also requires relatively high concentra-
tions of Angptl4, yet there is unequivocal evidence that Angptl4 serves
as physiological inhibitor of LPL in vivo [18,23,41]. It can be
hypothesized that the high concentrations of Angptl4 required for
in vitro LPL and PL inhibition may be related to absence of speciﬁc
factors that shift the dose response curve.
Whereas numerous exogenous intestinal lipase inhibitors have been
characterized, mainly representing plant derived components such as
saponins, polyphenols, and terpenes [42,43], to our knowledge we have
identiﬁed the ﬁrst endogenous inhibitor of PL. Interestingly, several
endogenous inhibitors of the major protein digestive enzymes including
trypsin and chemotrypsin have been described [44,45]. Although the
majority is thought to function in the pancreas to prevent premature
activation of zymogens [44], expression of some of these inhibitors is
found in the intestine [46,47], suggesting a role in controlling luminal
protease activity.
In recent years, the gut microbiota has received much attention as alleged
critical contributor to weight gain and obesity [48,49]. In this context, a role of
Angptl4 in linking gut microbiota to fat storage has been proposed.
Speciﬁcally, introducing microbiota into germ-free mice or zebraﬁsh was
found to markedly reduce intestinal Angptl4 expression [50,51]. Furthermore,
whereas wild-type and Angptl4 / mice have similar amounts of body fat
on a germ-free background, introducing microbiota leads to a much smaller
increase in body fat in Angptl4 / mice compared to wild-type mice,
suggesting that microbial suppression of Angptl4 contributes to increased fat
deposition. Suppression of Angptl4 was suggested to promote fat storage by
loss of inhibition of LPL activity in adipose tissue and reduction in expression
of Pgc1α and fatty acid oxidation enzymes in liver and skeletal muscle [52].
Based on our data, it can be envisaged that microbial suppression of Angptl4
may also promote weight gain via loss of local action of Angptl4 in the gut,
leading to elevated intestinal lipase activity and increased harvesting of dietary
TGs. In apparent conﬂict with the decrease in Angptl4 expression upon
colonization of germ-free animals, recent data suggest that short-chain fatty
acids derived from microbial fermentation of dietary ﬁbers induce Angptl4
expression in intestinal cells via PPARγ [38]. Although most of the short-chain
fatty acids are produced in the colon, relatively high concentrations are also
found in the small intestine [38]. It can be speculated that induction of
Angptl4 may play a role in mediating the repressive effect of dietary ﬁbers on
lipid absorption [53,54].
Angptl4 undergoes cleavage to form N-terminal and C-terminal Angptl4
fragments. Recently, we found that C-terminal Angptl4, which is unable to
inhibit lipase activity, is produced by entero-endocrine cells in human142 MOLECULAR METABOLISM 3 (2014) 135–144 & 2013 The Auintestine, suggesting secretion towards the bloodstream [55]. We hypothesize
that N-terminal Angptl4, which is able to inhibit lipase activity, is released
selectively by enterocytes towards the lumen to inhibit PL. Future experiments
will have to clarify both the exact site of N-terminal Angptl4 production as well
as its presence in the lumen.
We have previously shown that Angptl4 / mice develop a progressive
and ultimately lethal inﬂammatory condition when chronically fed a HFD
containing mainly saturated fatty acids [19]. However, it is highly unlikely
that the enhanced intestinal lipid uptake in Angptl4 / mice is related to
underlying inﬂammatory processes, as enhanced weight gain is already
apparent on a LFD and becomes more pronounced very quickly upon
shifting to a HFD. Furthermore, the effect of Angptl4 on luminal lipase
activity is apparent in mice fed a LFD or with tests that last only a
few hours.
Recently, Kim and colleagues postulated that Angptl4 deletion leads to
increased body weight due to an inhibitory effect of Angptl4
on hypothalamic AMPK and a subsequent increase in energy expendi-
ture [56]. In our study we were unable to ﬁnd a difference in energy
expenditure when comparing wild-type and Angptl4 / mice after a
1 week acclimatization to HFD, when the difference in weight gain
between the two sets of mice is the most pronounced. Additionally, Kim
and colleagues found that Angptl4 / mice have increased food
intake during fasting–refeeding, but not under ad libitum conditions [56].
Similarly, we have never observed any differences in food intake
between ad libitum-fed wild-type and Angptl4 / mice, either on
chow diet, semi-synthetic LFD or a HFD. Interestingly, the Angptl4 /
mice employed in the studies by Kim et al. were resistant to diet
induced obesity, while we have found several times that mice lacking
Angptl4 gain more weight on a HFD, at least during the ﬁrst 2 months. A
potential explanation for the difference is that the development of the
previously reported dietary saturated fat-induced inﬂammation in
Angptl4 / mice was greatly accelerated in the study by Kim and
colleagues due to extremely high saturated fat content of the diet,
leading to reduced food intake as described previously [19].
Collectively, we describe a novel function of Angptl4 in the regulation of
lipid metabolism. By acting as a gatekeeper in the regulation of intestinal
lipid uptake, Angptl4 decreases the amount of lipid being harvested from
the ingested food and protects against enterocyte lipid overload.ACKNOWLEDGMENTS
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